Funding Rounds
Epsilogen

Epsilogen Series B Round, September 2024

Epsilogen

Developer of immunoglobulin E (IgE) antibodies to treat cancer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $16.50M

Raised Date: 2024-09-09

Investors